Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLACENTAL HORMONES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23Linked to original sources
PubMed1986

High levels of growth hormone and human placental lactogen in pregnancy complicated by diabetes.

The possible involvement of growth hormone (GH) and human placental lactogen (HPL) in the development of diabetic tissue damage during pregnancy was studied in 16 insulin-dependent diabetic patients (IDDM), 8 gestational diabetic patients (GD) and 14 normal pregnant women. GH and HPL were elevated in pregnancies complicated by diabetes but, in contrast to the rise of HPL, GH declined throughout pregnancy in all the groups studied. The concentrations of neither correlated with plasma glucose, insulin requirement or duration of diabetes. HPL was positively correlated with urinary albumin excretion (UAE) in all 3 groups, but with blood pressure only in the IDDM group. There was also a significant and positive correlation in all patients between HPL at the end of pregnancy and placental weight. No evidence of serious tissue damage was found in either diabetic group. The vibration sensory threshold was unaffected by pregnancy and was similar to that of normal women. However, in the IDDM group UAE increased significantly postpartum when compared with second trimester values; they also had higher UAE than the other 2 groups post-delivery. A small but significant rise in diastolic blood pressure (DBP) was found in the 3 groups studied between the second and third trimester and pre-delivery. The same trend in systolic blood pressure (SBP) was seen in the diabetic groups. The IDDM had higher systolic and diastolic blood pressures than the normal women at all stages of gestation.

Adult↗
PubMed1996

Ectopic pregnancy: histopathology and assessment of cell proliferation with and without methotrexate treatment.

OBJECTIVE: To evaluate tubal morphology, trophoblast proliferation, and inflammatory reaction in response to methotrexate (MTX) treatment of ectopic pregnancy (EP). DESIGN: Nonrandomized controlled study. SETTING: Academic hospital. PATIENTS: Archival specimens from 10 EP unsuccessfully treated with MTX and 10 cases primarily treated by surgery. INTERVENTIONS: Ki67/hCG and Ki67/human placental lactogen double immunohistochemical methods were used to examine trophoblastic spread, placentation, hormone production, decidualization, vascular invasion, hemorrhage, rupture, and proliferative index of the cytotrophoblast. B and T-lymphocyte responses were evaluated by CD3 and CD20. RESULTS: Trophoblastic spread and placentation were confined to the tubal mucosa after MTX treatment, whereas invasion of the muscularis and subserosa was common in the controls. The proliferative index was reduced (19 percent versus 93 percent), although a high proliferative index was found in two of three cases complicated by rupture. Polar proliferation of Ki67-positive cytotrophoblast toward the implantation site was abolished in MTX-treated cases. Decidual reaction was not observed. No correlation was observed between the above-mentioned findings and gestational age, level of beta-hCG, dose of MTX, or interval to surgery. CONCLUSION: Trophoblastic spread, differentiation, and invasion were compromised by MTX treatment. Methotrexate seems to decrease cytotrophoblast proliferation. Whether a missing decrease in proliferation index reflects treatment failure awaits a larger population-based study.

Cell Division↗
PubMed1993

Acute stimulation of human chorionic gonadotropin secretion by recombinant human activin-A in first trimester human trophoblast.

Inhibin and activin are synthesized by the placenta, raising questions as to their functions in this tissue. The possibility of local regulation of other placental hormones critical during pregnancy was investigated by examining the effects of recombinant human inhibin-A and activin-A on hCG secretion. Potential interactions with GnRH-stimulated hCG secretion were also explored. First trimester human placental tissue was physically dissociated to isolate trophoblast cells. Cells were cultured on microcarrier beads for 7-10 days and loaded into 1.5-ml chambers in a perifusion system. After a 1-h control period, hormone treatments were administered in the perifusion medium for 5 min, and perifusate was collected for an additional 55 min. Perifusate fractions were analyzed for hCG concentration by RIA. Both activin and GnRH stimulated a rapid and transient hCG secretory response in the perifusion system. Unlike the effect of GnRH, the activin-stimulated hCG response was not blocked by concomitant treatment with a GnRH antagonist. The hCG RIA results were confirmed by preliminary experiments using a novel hCG bioassay. This suggested that activin did not facilitate hCG secretion by stimulation of endogenous GnRH release. Inhibin alone did not affect hCG secretion or GnRH-stimulated hCG secretion. However, treatment with inhibin and activin in combination resulted in a transient increase in hCG, followed by a decrease in hCG secretion to below pretreatment levels. The results suggested that in addition to GnRH, activin may play a role in the regulation of hCG secretion in first trimester placenta.

Activins↗
PubMed1991

Pregnancy after oocyte donation to a woman with ovarian failure and classical galactosemia.

In summary, oocyte and pre-embryo donation may be used to establish pregnancy in women with galactosemia and ovarian failure. Reported is the first pregnancy after pre-embryo donation to a woman with classical galactose-1-phosphate uridyl transferase deficiency. Despite disturbances in galactose metabolism, the endometrial lining responded normally to exogenous hormone replacement and was receptive to pre-embryo implantation. Pregnancy support was provided by exogenously administered oral E2 and IM P for the initial 100 days, at which time placental hormone production solely maintained the gestation.

Adult↗
PubMed1998

Tissue-specific messenger ribonucleic acid expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor within rat placenta suggests exquisite local control of glucocorticoid action.

Placental 11beta-hydroxysteroid dehydrogenase (11beta-HSD) regulates transplacental passage of maternal glucocorticoids to the fetus and is thus a key determinant of fetal glucocorticoid levels. It has also been proposed that placental 11beta-HSD expression may influence local glucocorticoid actions by regulating access of corticosterone to the glucocorticoid receptor (GR) or mineralocorticoid receptor (MR). Therefore, the present study used a rat model to assess whether the GR or MR are coexpressed with the two forms of 11beta-HSD (types 1 and 2) in the placental labyrinth zone, the major site of maternal-fetal transfer, and in the basal zone, the primary site of placental hormone synthesis. In situ hybridization analysis was used to assess messenger RNA (mRNA) expression for the GR, MR, 11beta-HSD-1, and 11beta-HSD-2 in the two placental zones on days 16, 19 and 22 of pregnancy (term = day 23). Whereas expression of the GR appeared relatively unchanged in both zones at these three stages of pregnancy, that of 11beta-HSD-1 clearly increased in the labyrinth zone but fell in basal zone, whereas the opposite pattern of expression was observed for 11beta-HSD-2. MR expression was not detected at any stage. The pattern of placental 11beta-HSD-2 mRNA expression over days 16, 19, and 22 of pregnancy was paralleled by changes in 11beta-HSD-2-specific bioactivity, but despite clear expression of 11beta-HSD-1 mRNA, no bioactivity attributable to this enzyme was measurable in either placental zone. To assess the role of fetal adrenal maturation on these changes in 11beta-HSD, two experimental models, maternal adrenalectomy and fetectomy, were employed. Maternal adrenalectomy on day 13 advanced maturation of the fetal adrenal cortex but had no effect on 11beta-HSD-2 bioactivity in either of the placental zones at day 19. Placental 11beta-HSD-2 bioactivity on day 22 was also unaffected by fetectomy 3 or 6 days earlier. In conclusion, the consistent expression of the GR in the two placental zones late in pregnancy suggests that concomitant and marked changes in 11beta-HSD-1 and 11beta-HSD-2 expression could have a major influence on glucocorticoid action in the placenta at this time. Moreover, the changes in 11beta-HSD expression appear to be unrelated to development of the fetal adrenal cortex and are likely to reduce the placental glucocorticoid barrier near the end of pregnancy.

11-beta-Hydroxysteroid Dehydrogenases↗
PubMed1991

Blockade of the antigen-antibody reaction using benzil condensation with the guanidyl residue of arginine.

Benzil blockade of the guanidyl group of arginine was tried on sections of paraffin-embedded tissue fixed in two different fixatives, in an attempt to evaluate the relevance of this amino acid to the reaction of several proteins with their corresponding antibodies. The two fixatives were 10% formaldehyde, and Bouin's fluid without acetic acid. Both polyclonal and monoclonal antibodies against proteins or peptides (lysozyme, adrenocorticotropic hormone, growth hormone, placental lactogen, and prolactin) were used on human biopsies or material from autopsies. The blockade was effective when monoclonal antibodies were used, whereas no effect or only a small decrease of the intensity of the reaction was observed with polyclonal antibodies. The least definitive result was obtained with prolactin, where a complete blockade was never achieved with monoclonal antibodies. Calcitonin, a peptide that does not contain arginine, was used as a control not susceptible to benzil blockade; no blockade of immunostaining was observed.

Adrenocorticotropic Hormone↗
PubMed1979

Differences in localization of insulin receptors and adenylate cyclase in the human placenta.

The interactions of hormones with plasma membranes in the human placenta were characterized for specific fetal and maternal components. The microvillus brush border membrane, which is exposed to maternal blood in the intervillous space, was markedly enriched in specific insulin receptors but contained no hormone-sensitive adenylate cyclase. On the other hand, a basal plasma membrane fraction, which is presumably exposed more directly to fetal hormones, contained adenylate cyclase which was sensitive to prostaglandins, epinephrine, and fluoride but was not enriched in insulin receptors or other brush border markers. This study demonstrates separate fetal and maternal aspects of placental-hormone interactions. This separation and the relative impermeability of the placenta to hormones may allow for independent maternal and fetal components of the interaction of hormones with the placenta.

Adenylyl Cyclases↗
PubMed1978

Contribution of maternal circulation to blood-borne progesterone in the fetus. II. Studies on sheep.

Catheters were placed in maternal and fetal vessels in four ewes in the last month of gestation. Tritiated progesterone (P) was infused at a constant rate into a maternal peripheral vein. Specific activities and endogenous concentrations of P were measured in blood samples drawn from a maternal artery and either a fetal femoral artery or an umbilical vein. Comparison of the specific activities of P in fetal and maternal samples revealed that direct secretion of the placental hormone into the umbilical vein accounted for 90 to 93 per cent of the hormone in the fetal circulation. Estimates of the rates of production of P in the fetal circulation, obtained by multiplying metabolic clearance rates previously reported and concentrations of P in a fetal femoral artery, indicate that placental P is preferentially secreted toward the maternal circulation.

Animals↗
PubMed1991

Circulating levels of inhibin in pregnant women at term: simultaneous disappearance with oestradiol and progesterone after delivery.

Circulating levels of immunoreactive inhibin (ir-inhibin) and its disappearance after delivery of the placenta were determined in seven pregnant women at term. Serum oestradiol (E2) and progesterone (P4) levels were measured simultaneously and served as comparisons. Fetal contributions of ir-inhibin were assessed by determining concentrations in the umbilical artery (UA) and vein (UV). Relative changes in circulating levels of ir-inhibin, E2, and P4 were compared to levels found in nonpregnant women during the early follicular phase (EFP) and mid-luteal phase (MLP) of the normal menstrual cycle. In pregnant women, ir-inhibin levels at delivery were 15- and 3-fold higher than EFP and MLP values respectively. The disappearance of all three hormones after removal of the placenta followed a bi-exponential curve with an initial, rapid component and a second, slower component. There was a highly significant positive correlation between the disappearance curves of all three placental hormones (r = 0.97, P less than 0.0001). Concentrations of ir-inhibin in the cord blood were about half that in maternal serum and without significant difference between levels in UA and UV.

Adolescent↗
PubMed1990

Elevated maternal plasma corticotropin releasing hormone levels in twin gestation.

The placenta secretes large amounts of the hypothelamic hormone, corticotropin releasing hormone (CRH) into the maternal and fetal circulation during pregnancy. We and other investigators have shown that during normal pregnancy, maternal plasma CRH levels begin to rise in the second trimester with a dramatic increase in CRH levels during the 5-6 weeks preceding the onset of labor. This rise in maternal plasma CRH is parallel to the rise of placental CRH mRNA which has been reported to occur with gestational maturation. Mechanisms underlying the control of CRH secretion by the placenta have not yet been determined. In twin gestation, increased fetal-placental mass has been shown to be associated with elevated maternal levels of several placental hormones as compared to singleton gestation. We measured maternal plasma CRH in both twin and singleton gestation to investigate whether the larger size of the fetal-placental unit in twin gestation is associated with elevated maternal CRH levels. Seventy-six serial venous blood samples were collected from 20 women with twin gestation and 40 samples were obtained from 27 women with uncomplicated singleton gestation. Gestational age was determined by history of a known last menstrual period and first trimester clinical examination and confirmed by ultrasound examination. CRH was extracted from 1-2 ml plasma with SEP-Pak C18 cartridges and eluted with triethylamine-formic-acid propranolol. CRH was measured by radioimmunoassay (RIA) with human CRH standard and antiserum to human CRH raised in our laboratory. Mean CRH levels were calculated for four week intervals. In both singleton and twin gestation, the maternal plasma CRH levels increased with advancing gestational age. After 29 weeks of gestation, maternal plasma CRH levels in twin gestation were significantly higher than those in singleton gestation (p less than 0.01). At 37 to 40 weeks of gestation, mean maternal CRH was 1167 +/- 237 pg/ml in singleton gestation as compared to 6927 +/- 1725 pg/ml in twin gestation (p less than 0.05). In addition, the rapid rise in plasma CRH levels which occurs near term in singleton gestation, occurred earlier in twin gestation. This early rise in maternal CRH levels persisted when the data from twin pregnancies complicated by preterm labor were removed from the analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Corticotropin-Releasing Hormone↗
PubMed1978

Contribution of maternal circulation to blood-borne progesterone in the fetus. I. Studies on human subjects.

Tritiated progesterone was infused intravenously at a constant rate into three pregnant volunteers in labor, for at least two hours before delivery. Blood samples from a maternal peripheral vein and from unbilical vessels were taken at birth. Comparison of the specific activities of progesterone in these samples indicated that 10 per cent or less of the hormone in fetal circulation is derived from transfer of maternally circulating progesterone. After consideration of reported values of umbilical vein blood flow at term and measured arteriovenous differences in concentrations of progesterone in umbilical vessels, the secretion rate of the placental hormone toward the fetus was estimated to be about 1/10 of the rate of secretion of progesterone toward the maternal circulation. About 1 per cent of the maternally circulating hormone was found to cross the placenta.

Female↗
PubMed2000

Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings.

Estrogens along with progesterone/progestins, and other hormones, are important determinants of cancer in the breast, endometrium and ovary. Estrogens may increase the risk of breast cancer through various mechanisms and at various phases of life, with a possible synergistic effect of progesterone/progestins. Exposure to high doses of placental hormones, such as estrogens and/or progesterone, during pregnancy may play a pivotal role in reducing subsequent breast cancer susceptibility. Estrogens cause endometrial cancer, an effect that can be reduced, prevented or reversed by progesterone/progestin - if allowed to act for a sufficiently long period of each cycle. The role of sex hormones seems important for ovarian carcinogenesis. Intake of combined oral contraceptives has a substantial and well-documented protective effect on endometrial and ovarian cancer risks. Epidemiological observations and experimental data from an animal model indicate that estrogens may have an adverse effect, while progesterone/progestins have a risk reducing effect directly on the ovarian epithelium. Thus, estrogens and other sex hormones have potential effects on the three most important female cancers. Research has yet to define how some of the risk factors can be modified or treatment regimens can be improved to reduce these cancer risks.

Age Factors↗
PubMed1981

Recombinant hormones from fragments of human growth hormone and human placental lactogen.

Peptide fragments generated by limited plasmin digestion and reduction of human growth hormone (hGH) and human placental lactogen (hPL) were recombined to produce biologically active molecules consisting of the NH2-terminal two-thirds of one hormone molecule linked to the COOH-terminal one-third of the other. Plasmin-cleaved hPL and hGH each consist of an NH2-terminal fragment (1-134) connected to a COOH-terminal fragment (141-191) through a Cys53-Cys165 disulfide bond. The plasmin-cleaved hormones were reduced, the fragments isolated, and then recombined in equimolar quantities to prepared recombinant hormones. On sodium dodecyl sulfate disc gel electrophoresis the recombinants migrated as a single band in the position of native hormone when they were not reduced and as two bands in the positions of the fragments when they were reduced. This indicated that the recombinants had re-formed a disulfide bond. The derivatives were tested for immunologic activity in hPL and hGH radioimmunoassays, for lactogenic and growth-promoting activity by the radioreceptor assays using membranes from mammary gland and liver of lactating rabbits, and for secondary and tertiary structure by circular dichroism measurements in the near and far UV regions. The recombinant with NH2-terminal hGH had hGH immunologic activity, hGH structure and lactogenic and growth-promoting activity, while the hybrid with NH2-terminal hPL had hPL immunologic activity, hPL structure, and lactogenic activity alone. Therefore the immunologic activity, biologic activity, and structure of each of the covalently linked derivatives was characteristic of the hormone's NH2-terminal 1-134 fragment. The COOH-terminal 141-191 sequence maintains overall conformation but appears to have little, if any, role in determining biologic specificity.

Amino Acids↗
PubMed1987

Monoclonal antibodies against human, bovine and rat prolactin: epitope mapping of human prolactin and development of a two-site immunoradiometric assay.

Nine mouse hybridoma cell lines producing monoclonal antibodies (MCA) against human prolactin (hPRL), 19 cell lines against bovine prolactin (bPRL) and one MCA against rat prolactin (rPRL) were established. The MCA were characterized by one- and two-site radioimmunoassays (RIA) as well as indirect immunofluorescence (IIF) and used for epitope mapping of hPRL and immunoradiometric assays (IRMA). Interspecies cross-reactivity studies by RIA revealed two groups of anti-hPRL MCA: seven which reacted only with hPRL and two additionally recognizing bPRL and ovine prolactin (oPRL). The anti-bPRL MCA, which were tested on pituitary sections by IIF could be divided into 17 MCA cross-reacting with the closely related oPRL, and two MCA which showed additional cross-reactions with equine prolactin. The anti-rPRL antibody reacted exclusively with rPRL in direct binding RIA studies. No intraspecies cross-reactions with the closely related protein hormones placental lactogen and GH were detected. To elucidate the antigenic surface of hPRL all MCA directed against hPRL were then used for two-site epitope mapping studies in which pairs of MCA were assessed for simultaneous reaction with the same antigen. The native hormone was incubated with the first, solid-phase bound, so called 'capture MCA', and this complex treated with a second, 125I-labelled 'detection MCA'. Based on the results of these combinations, at least three sterically non-overlapping and (taking RIA cross-reaction studies into consideration) two additional epitopes could be defined.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMedDate not supplied

Placenta accreta: an immunohistological study of trophoblast populations.

Trophoblast populations in four cases of placenta accreta were characterized using antibodies directed against cell membrane antigens, placental hormonal products and low-molecular-weight cytokeratins in standard immunoperoxidase techniques. The results obtained with antibody to syncytiotrophoblast membrane (rabbit anti-StMPM), antibody to an epithelial membrane antigen (HMFGI) and a cytokeratin marker (CAM 5.2) appeared identical to those reported for normal term placental tissues. Similarly the localization of human placental lactogen (hPL), human chorionic gonadotrophin (hCG) and pregnancy-specific beta 1-glycoprotein (SP1) within trophoblast populations in placenta accreta was identical to their reported distribution in term placenta. However, increased reactivity at the villous-maternal junction was demonstrated with NDOGI, an antibody raised against term syncytiotrophoblast membrane and directed against hyaluronic acid. NDOGI reactivity at this site is normally maximal during early placental development and is virtually absent in the third trimester. The results suggest that placenta accreta does not arise through excessive trophoblast invasiveness or proliferation and the absence of decidua is of more importance in the pathogenesis. Trophoblast may regulate its development at an unfavourable intramyometrial implantation site by the production of hyaluronic acid.

Antigens, Surface↗
PubMed2006

The pleiotropic function of PPAR gamma in the placenta.

At different stages of placental development the cytotrophoblasts differentiate into specialized cells that are vital for specific placental tasks. These types include the invasive trophoblasts, which are responsible for invasion of the placenta into the uterine wall, and syncytiotrophoblasts, which form a barrier between the maternal and fetal circulations, govern trans-placental transport of gas, nutrient and waste, and produce placental hormones. Recent research illuminated the role of the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma) in the areas of adipocyte and macrophage biology, insulin action, bioenergetics and inflammation. It was somewhat surprising that PPAR gamma was also found to play a pivotal role in placental biology. In this review we summarize recent data, which show that PPAR gamma is expressed in the placenta, particularly in trophoblasts, and is essential for placental development, trophoblast invasion, differentiation of cytotrophoblasts into syncytium, and regulation of fat accumulation in trophoblasts. PPAR gamma may also play a role in modulating fetal membrane signals toward parturition. The data presented here underscore the need for a focused investigation of the unique aspects of PPAR gamma function in trophoblasts, which may have direct implications for the use of PPAR gamma ligands during pregnancy.

Animals↗
PubMed1979

A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments.

An unexpected 20-week-old pregnancy was found in a young acromegalic who had been treated with 10 mg bromocriptine/day for 10 months. The drug was continued throughout the period of gestation. No growth of the pituitary adenoma was noticed. The intrauterine development of the fetus was normal. Bromocriptine therapy had no discernible effect on the expected patterns of secretion of placental hormones, but inhibited completely the increase of PRL in the serum of the mother. Maternal plasma GH concentrations were very high in spite of the treatment and progressively declined after delivery. The plasma GH level was normal in the child, but PRL was very low at birth and increased in the following days. The expected high PRL concentration was found in the amniotic fluid. This case study suggests that bromocriptine crosses the human placenta and affects the fetal pituitary, maternal GH does not influence fetal or amniotic GH, and amniotic fluid PRL correlates poorly with either maternal or fetal blood levels and is not affected by bromocriptine.

Acromegaly↗
PubMedDate not supplied

Trophoblast cell differentiation and organization: role of fetal and ovarian signals.

The rat chorioallantoic placenta is organized into two distinct zones (junctional and labyrinth) and expresses six members of the placental prolactin (PRL) family: placental lactogen-I (PL-I), PL-I variant (PL-Iv), PL-II, PRL-like protein-A (PLP-A), PLP-B, and PLP-C. These placental hormones are expressed in distinct cell- and temporal-specific patterns and can be used to monitor the state of differentiation of rat trophoblast cells. This study was initiated to examine the role of the fetus and maternal ovaries in the regulation of trophoblast cell differentiation and organization. Expression of the placental PRL family was monitored by Northern and Western blotting and immunocytochemical analysis. The roles of the fetus and maternal ovaries were examined by chemically induced fetal death (DFX, induced by intraamniotic injection of digoxin) and surgical removal of the ovaries (OVX), respectively. The endocrine differentiation of the placenta was assessed on day 19 of gestation (sperm positive = day 0, parturition = day 21). Day 10 of gestation was the earliest day that DFX could be reliably performed. Day 10 is a time point during pregnancy preceding the onset of expression of all members of the placental PRL family except PL-I. DFX on day 10 of gestation did not affect the endocrine differentiation of the trophoblast cells but did alter the organization of the chorioallantoic placenta. PL-II, PL-Iv, and the PLPs were all expressed in their appropriate molecular forms and cell types in placentas developing in the absence of fetal influence. The maternal ovaries, in the absence of the fetus, had two distinct actions on the placenta: ovarian signals were essential during a period at midgestation for the maintenance of the placenta and exposure of the developing placenta to ovarian signals during the second half of gestation, in the absence of the fetus, arrested labyrinth zone development. The active ovarian signals were progesterone and estrogen. We conclude that trophoblast cell differentiation occurs independent of the fetus and maternal ovaries. However, signals from both the fetus and maternal ovaries are required for normal organization of the chorioallantoic placenta.

Alkaline Phosphatase↗